Key Professional Analysts at BMO Capital Didn’t Change their ‘Outperform’ rating for Spark Therapeutics (NASDAQ:ONCE) Shares Today. Their Price Target Given is $78

May 9, 2018 - By Richard Conner

Spark Therapeutics, Inc. (NASDAQ:ONCE) Logo

Investors sentiment decreased to 1.43 in Q4 2017. Its down 1.51, from 2.94 in 2017Q3. It worsened, as 41 investors sold Spark Therapeutics, Inc. shares while 26 reduced holdings. 41 funds opened positions while 55 raised stakes. 35.76 million shares or 6.30% more from 33.64 million shares in 2017Q3 were reported.

Moreover, Victory Cap has 0% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE). Baker Bros Advsrs L P invested 0.62% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Landscape Capital Mngmt Ltd Liability Com invested in 27,073 shares. Teachers Retirement Sys Of The State Of Kentucky holds 0.01% in Spark Therapeutics, Inc. (NASDAQ:ONCE) or 22,954 shares. Retirement Systems Of Alabama stated it has 0.01% of its portfolio in Spark Therapeutics, Inc. (NASDAQ:ONCE). Envestnet Asset owns 115 shares for 0% of their portfolio. Voya Investment Mgmt Lc invested in 12,203 shares or 0% of the stock. Wellington Grp Llp owns 0.04% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 3.12M shares. Element Mngmt Ltd Com stated it has 155,988 shares or 0.2% of all its holdings. Geode Capital Ltd Liability reported 0% stake. State Of Wisconsin Inv Board reported 0% of its portfolio in Spark Therapeutics, Inc. (NASDAQ:ONCE). Rockefeller Fincl Services Incorporated owns 353,983 shares. Schwab Charles owns 0.01% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 144,632 shares. Quantitative Investment Mngmt Ltd holds 0.06% of its portfolio in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 83,400 shares. Td Asset Mngmt invested in 0.01% or 85,066 shares.

Spark Therapeutics (NASDAQ:ONCE) Rating Reaffirmed

BMO Capital now has a $78 target price per share on shares of Spark Therapeutics (NASDAQ:ONCE). The target price per share would suggest a potential upside of 2.60 % from the last price of Spark Therapeutics (NASDAQ:ONCE). This rating was shown in analysts report on Wednesday morning.

Spark Therapeutics, Inc. (NASDAQ:ONCE) Ratings Coverage

Among 18 analysts covering Spark Therapeutics (NASDAQ:ONCE), 10 have Buy rating, 1 Sell and 7 Hold. Therefore 56% are positive. Spark Therapeutics has $105.0 highest and $40.0 lowest target. $70.50’s average target is -7.26% below currents $76.02 stock price. Spark Therapeutics had 35 analyst reports since December 11, 2017 according to SRatingsIntel. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) has “Buy” rating given on Wednesday, February 21 by Bernstein. The firm has “Neutral” rating by JP Morgan given on Wednesday, February 14. JP Morgan maintained it with “Neutral” rating and $63 target in Tuesday, May 1 report. BMO Capital Markets maintained it with “Buy” rating and $66.0 target in Wednesday, January 24 report. The firm earned “Buy” rating on Tuesday, May 1 by Mizuho. The company was maintained on Wednesday, May 9 by Stifel Nicolaus. Leerink Swann downgraded the stock to “Hold” rating in Tuesday, December 12 report. On Monday, April 30 the stock rating was maintained by Cantor Fitzgerald with “Buy”. As per Tuesday, February 20, the company rating was maintained by Cantor Fitzgerald. The firm has “Buy” rating given on Monday, December 11 by Cantor Fitzgerald.

The stock increased 8.96% or $6.25 during the last trading session, reaching $76.02. About 1.01 million shares traded or 56.31% up from the average. Spark Therapeutics, Inc. (NASDAQ:ONCE) has risen 21.52% since May 10, 2017 and is uptrending. It has outperformed by 9.97% the S&P500.

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company has market cap of $2.83 billion. The Company’s products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. It currently has negative earnings. The companyÂ’s products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A.

More notable recent Spark Therapeutics, Inc. (NASDAQ:ONCE) news were published by: Globenewswire.com which released: “Spark Therapeutics Sells Priority Review Voucher for $110 Million” on April 30, 2018, also Seekingalpha.com with their article: “Spark Therapeutics’ (ONCE) CEO Jeff Marrazzo on Q1 2018 Results – Earnings Call Transcript” published on May 08, 2018, Nasdaq.com published: “Detailed Research: Economic Perspectives on Vitamin Shoppe, Surmodics, Spark Therapeutics, QUANTENNA …” on May 01, 2018. More interesting news about Spark Therapeutics, Inc. (NASDAQ:ONCE) were released by: Seekingalpha.com and their article: “Spark Therapeutics 2018 Q1 – Results – Earnings Call Slides” published on May 08, 2018 as well as Seekingalpha.com‘s news article titled: “Ionis Pharmaceuticals: The Pinnacle Of RNA Therapeutic Innovation” with publication date: April 30, 2018.

Spark Therapeutics, Inc. (NASDAQ:ONCE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: